<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347332</url>
  </required_header>
  <id_info>
    <org_study_id>L00070 IN 309 F0</org_study_id>
    <nct_id>NCT02347332</nct_id>
  </id_info>
  <brief_title>Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer</brief_title>
  <official_title>Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients relapsing after platinum-based therapy, few data are available. The current use
      of cetuximab associated with radiotherapy in localized disease and associated with
      platinum-based chemotherapy in the first-line setting stresses the need for new therapeutic
      options at later stages of SCCHN.Vinca-alkaloids demonstrated activity in SCCHN. Vinflunine
      demonstrated superior antitumour activity to vinorelbine in preclinical animal models. Recent
      preliminary phase I results of the vinflunine plus methotrexate combination in SCCHN, based
      on a clinical review, show encouraging antitumour activity and an acceptable safety profile.
      Therefore the combination of vinflunine and methotrexate appears a promising salvage regimen
      after platinum failure.

      The present study has been designed as a multicenter, randomised phase III study which will
      compare the combination of IV vinflunine with methotrexate to methotrexate alone in SCCHN
      patients having failed platinum-based therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>participants will be followed till death (if they are not lost for follow-up), an expected average of 7.5 months</time_frame>
    <description>time measured from the date of randomisation up to death or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>an expected average of 4 months</time_frame>
    <description>time measured from the date of randomisation until date of progression or death from any cause (whichever came first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response and disease control rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Recurrent or Metastatic Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Vinflunine plus methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinflunine</intervention_name>
    <arm_group_label>Vinflunine plus methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed recurrent and/or metastatic squamous cell
             carcinoma

          -  Documented progressive disease after chemotherapy for locoregionally advanced or
             recurrent/metastatic SCCHN which included a platinum derivative

          -  Measurable or non measurable disease

          -  adequate haematological, hepatic and renal functions

          -  WHO performance status &lt; 1

        Exclusion Criteria:

          -  Nasopharyngeal carcinoma

          -  History of brain or leptomeningeal involvement

          -  Albumin level &lt; 35 g/L

          -  Patients with weight loss ≥ 5% within the last 3 months

          -  Grade &gt; 2 peripheral neuropathy at study entry

          -  &quot;Third space&quot; fluids (pleural effusion, ascites, massive edema)

          -  Prior treatment with vinca-alkaloids and methotrexate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Keddad</last_name>
    <role>Study Director</role>
    <affiliation>Pierre Fabre Medicament</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

